Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inflammation A Clue Left In ACCELERATE CETP Wreckage

Executive Summary

Blood pressure and C-reactive protein were modestly increased in the ACCELERATE trial of Lilly’s CETP inhibitor evacetrapib, but what exactly torpedoed the trial is still a mystery.

Advertisement

Related Content

Merck Calls It Quits On Anacetrapib
Merck Calls It Quits On Anacetrapib
Merck Loses Chance For Primary Care Blockbuster With Odanacatib Failure
Where Cholesterol Surrogates Stand After ACC '16
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057588

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel